Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock, effective from August 18, 2025.
The reverse stock split aims to regain compliance with Nasdaq listing requirements.
This decision was approved by the Company's Board of Directors and shareholders.
Reverse Stock Split
Entero Therapeutics, Inc. is implementing a 1 for 3 reverse stock split to maintain Nasdaq listing compliance.
Share Consolidation
Every 3 shares will be combined into 1 share, reducing outstanding common stock from 4.77 million to 1.59 million shares.
Fractional Shares
No fractional shares will be issued; stockholders entitled to receive fractional shares will receive cash instead.
- The visibility and credibility associated with a Nasdaq listing are crucial for Entero Therapeutics, Inc. to enhance shareholder value.
- The reverse stock split aims to support the Company in its efforts to maintain a listing on the Nasdaq market.
Entero Therapeutics, Inc.'s reverse stock split demonstrates the Company's commitment to meeting Nasdaq listing requirements and enhancing shareholder value in the long term.